Has John Ader, DO received payments from drug or device companies?

Yes. Drug and device makers reported $363 in general payments to John Ader, DO across 53 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Ader, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Ader, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Ader, DO

Rheumatology · Post Falls, IDNPI 1992789564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Amgen at 48.4% of the total. That places this record below the midpoint for rheumatology clinicians in ID, where the typical reported total is $1,851.

$363in general payments, 2019–2025

Across 53 payments — averaging $6.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$176
Pfizer$158
E.r. Squibb & Sons, L.L.C.$16
AbbVie$13

What the payments were for

Food & beverage$363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	17	$176
Pfizer	34	$158
E.r. Squibb & Sons, L.L.C.	1	$16
AbbVie	1	$13

How this compares

$363 in reported general payments places this provider in the 30th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho →

Medicare billing

Part B allowed, 2024

$34,506

Medicare patients

128

Services billed

706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	54	$450,223
SimponiGolimumab	21	$195,306
Humira(Cf)Adalimumab	19	$127,427
Cosentyx Sensoready PenSecukinumab	13	$93,365
Taltz AutoinjectorIxekizumab	11	$73,620
EnbrelEtanercept	13	$48,964
Leflunomide	248	$15,696
Hydroxychloroquine Sulfate	298	$9,019
MethotrexateMethotrexate Sodium	169	$2,154
Allopurinol	69	$641
Alendronate Sodium	112	$630
Sulfasalazine	15	$587
Sulfasalazine DrSulfasalazine	20	$502
Prednisone	87	$387
Folic Acid	23	$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieHumira(Cf)	$13	$127,42719 claims
AmgenEnbrel	$176	$48,96413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 28 rheumatology providers in Idaho.